Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity by Woodford, Mark R et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
10-8-2019 
Mutation of the co-chaperone Tsc1 in bladder cancer diminishes 
Hsp90 acetylation and reduces drug sensitivity and selectivity 
Mark R. Woodford 
Michael Hughes 
Rebecca A. Sager 
Sarah J. Backe 
Alexander J. Baker-Williams 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Mark R. Woodford, Michael Hughes, Rebecca A. Sager, Sarah J. Backe, Alexander J. Baker-Williams, 
Michael S. Bratslavsky, Joseph M. Jacob, Oleg Shapiro, Michael Wong, Gennady Bratslavsky, Dimitra 
Bourboulia, and Mehdi Mollapour 
Oncotarget5824www.oncotarget.com
Mutation of the co-chaperone Tsc1 in bladder cancer diminishes 
Hsp90 acetylation and reduces drug sensitivity and selectivity
Mark R. Woodford1,2,3,*, Michael Hughes1,3,*, Rebecca A. Sager1,2,3,4,*, Sarah J. 
Backe1,2,3, Alexander J. Baker-Williams1,2,3, Michael S. Bratslavsky1,3, Joseph 
M. Jacob1,3, Oleg Shapiro1,3, Michael Wong5,6, Gennady Bratslavsky1,2,3, Dimitra 
Bourboulia1,2,3 and Mehdi Mollapour1,2,3
1Department of Urology, SUNY Upstate Medical University Syracuse, NY 13210, USA
2Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University Syracuse, NY 13210, USA
3Upstate Cancer Center, SUNY Upstate Medical University Syracuse, NY 13210, USA
4College of Medicine, SUNY Upstate Medical University Syracuse, NY 13210, USA
5Department of Neurology, Washington University School of Medicine, Saint Louis, MO 63110, USA
6Hope Center for Neurological Disorders, Washington University School of Medicine, Saint Louis, MO 63110, USA
*These authors contributed equally to this work
Correspondence to: Mehdi Mollapour, email: mollapom@upstate.edu 
Dimitra Bourboulia, email: bourmpod@upstate.edu
Keywords: tuberous sclerosis complex (TSC); Tsc1 (Hamartin); Tsc2 (Tuberin); heat shock protein (Hsp90); bladder cancer
Received: July 23, 2019    Accepted: August 29, 2019     Published: October 08, 2019
Copyright: Woodford et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
The molecular chaperone Heat shock protein 90 (Hsp90) is essential for the 
folding, stability, and activity of several drivers of oncogenesis. Hsp90 inhibitors are 
currently under clinical evaluation for cancer treatment, however their efficacy is 
limited by lack of biomarkers to optimize patient selection. We have recently identified 
the tumor suppressor tuberous sclerosis complex 1 (Tsc1) as a new co-chaperone 
of Hsp90 that affects Hsp90 binding to its inhibitors. Highly variable mutations of 
TSC1 have been previously identified in bladder cancer and correlate with sensitivity 
to the Hsp90 inhibitors. Here we showed loss of TSC1 leads to hypoacetylation 
of Hsp90-K407/K419 and subsequent decreased binding to the Hsp90 inhibitor 
ganetespib. Pharmacologic inhibition of histone deacetylases (HDACs) restores 
acetylation of Hsp90 and sensitizes Tsc1-mutant bladder cancer cells to ganetespib, 
resulting in apoptosis. Our findings suggest that TSC1 status may predict response to 
Hsp90 inhibitors in patients with bladder cancer, and co-targeting HDACs can sensitize 
tumors with Tsc1 mutations to Hsp90 inhibitors.
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INTRODUCTION
Over 80,000 people will be diagnosed with bladder 
cancer and approximately 18,000 patients will die 
from this disease in the United States in 2019 [1]. The 
vast majority of bladder cancer cases are urothelial cell 
carcinomas (90%) followed by squamous cell carcinomas 
(5%) with the remaining cases being made up of rare 
entities including sarcoma and small cell carcinoma 
[2]. Bladder cancer has the highest lifetime cost of all 
cancers, which is attributed to high recurrence rates and 
the invasive monitoring required in the management of 
this disease [3]. Depending on stage, standard of care 
in management of bladder cancer may include local 
resection, chemotherapy, immunotherapy, radiotherapy, 
or partial or radical cystectomy [4]. Advancements in 
the treatment of metastatic disease have been few, with 
alternatives to chemotherapeutic mainstay therapies 
offering limited survival benefit [5, 6].
The molecular chaperone heat shock protein-90 
(Hsp90) is essential for the stabilization and activation 
of many oncogenic proteins, known as clients, involved 
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in malignant transformation of tumor cells [7–9]. Hsp90 
chaperone function is coupled to its ability to bind and 
hydrolyze ATP [10–12]. This ATPase activity provides 
directionality to the Hsp90 chaperone cycle, which is 
tightly regulated by both co-chaperone proteins and post-
translational modifications [13–15]. Numerous small 
molecules have been identified that compete with ATP 
for binding to the amino-domain of Hsp90 and inhibit its 
chaperone function, leading to the degradation of many 
client proteins involved in tumorigenesis [7]. There are 
currently 7 Hsp90 inhibitors in clinical trials (https://www.
clinicaltrials.gov/), and there is an urgent need to identify 
biomarkers to help identify those patients that would 
respond favorably to treatment with Hsp90 inhibitors [16].
We have recently identified the tumor suppressor 
TSC1 as a novel regulator/co-chaperone of Hsp90 
important for the folding and stability of numerous kinase 
and non-kinase clients including Tsc2 protein (tuberin) 
[17]. Tsc2 protein has a GTPase-activating function and in 
complex with Tsc1 protein (hamartin) and possibly Hsp90 
acts as a negative regulator of AMPK/mTOR signaling 
[18–20]. Additionally, Tsc1 assists in the deceleration of 
Hsp90 ATPase activity and the Hsp90 chaperone cycle, 
and Tsc1 expression increases Hsp90 binding to its 
inhibitors [17].
Mutation and inactivation of the tumor suppressor 
TSC1 has been found in approximately 15% of bladder 
cancers and loss of heterozygosity of a region spanning 
the TSC1 locus at 9q34 has been seen in roughly 54% of 
bladder cancers [21–26]. We therefore hypothesized that 
mutation and inactivation of TSC1 in bladder cancer cells 
leads to decreased sensitivity to Hsp90 inhibitors. Our 
data supported this hypothesis, and we mechanistically 
demonstrated that mutation and loss of TSC1 in bladder 
cancer cells causes hypoacetylation of Hsp90-K407/
K419 and subsequent decreased binding of Hsp90 to its 
inhibitor ganetespib. Pharmacologic inhibition of histone 
deacetylases (HDACs) restores acetylation of Hsp90 and 
sensitizes Tsc1-mutant bladder cancer cells to ganetespib, 
resulting in apoptosis. Our results suggest that Tsc1 status 
can predict response to Hsp90 inhibition in bladder cancer 
patients and further provide a strategy to co-target HDACs 
and Hsp90 in bladder cancers with mutation in TSC1.
RESULTS
Tsc1 expression determines Hsp90 inhibitor 
accumulation and sensitivity in bladder cancer 
cells
Our previous study has shown that the presence of 
Tsc1 co-chaperone, which interacts with Hsp90 through 
the C-terminus of Tsc1, enhances Hsp90 binding to 
its inhibitors in cells [17]. Here, we used biotinylated 
inhibitor ganetespib (GB-biotin) to determine the binding 
affinity of Hsp90 from T24 and UM-UC-3 cells, which 
express wild-type (WT) TSC1 as well as RT4 cells that 
have a TSC1 mutation (1669delC), which leads to a 
frame shift and premature stop codon, rendering the 
protein product (Tsc1-L557Cfs) unstable (Figure 1A, 1B; 
Supplementary Figure 1A) [27]. Our data showed that 
Hsp90 binding was significantly reduced in TSC1 mutated 
RT4 cells compared to TSC1 WT T24 and UM-UC-3 
bladder cancer cells (Figure 1B, Supplementary Figure 
1B). We have further demonstrated that presence of Tsc1 
facilitates accumulation of fluorescently-tagged Hsp90 
inhibitor, BODIPY-ganetespib, in bladder cancer cells 
after 4 hours of treatment (Figure 1C, 1D; Supplementary 
Figure 1C–1E). This ganetespib accumulation was 
reduced when TSC1 was silenced by siRNA in T24 and 
UM-UC-3 cells (Figure 1C, 1D; Supplementary Figure 
1C, 1D). Conversely, re-expression of WT Tsc1 in RT4 
cells restored uptake and retention of ganetespib in these 
bladder cancer cells (Figure 1C, 1D; Supplementary 
Figure 1C, 1E). In addition to the effect on inhibitor 
accumulation, TSC1 expression also significantly 
sensitized RT4 bladder cancer cells to Hsp90 inhibitor 
as evidenced by WST proliferation assay (Figure 1E). 
Conversely, silencing of TSC1 in T24 and UM-UC-3 cells 
reversed their sensitivity to ganetespib. Taken together, 
these data show that presence of Tsc1 enhances bladder 
cancer cell sensitivity and uptake of Hsp90 inhibitors.
Tsc1 facilitates acetylation of Hsp90
Previous studies from our lab and others have shown 
that post-translation modification (PTM) of Hsp90 impacts 
its binding to as well as sensitizes cells to Hsp90 inhibitors 
[15, 28–30]. We therefore asked whether absence of Tsc1 
impacts the PTM of Hsp90. We showed hypoacetylation 
of Hsp90 in CRISPR/Cas9 TSC1 KO HAP1 compared to 
WT HAP1 cells (Figure 2A; Supplementary Figure 2A). 
Interestingly, lack of TSC1 did not affect phosphorylation 
of Hsp90 on serine, threonine, or tyrosine residues (Figure 
2A). Expression of WT TSC1 in TSC1 KO HAP1 cells 
restored acetylation of Hsp90, however we did not obtain 
similar results upon overexpression of Tsc1-L557Cfs 
(Figure 2B). We made a similar observation in RT4 cells, 
which contain the Tsc1-L557Cfs mutation and showed 
hypoacetylation of Hsp90 relative to WT Tsc1 containing 
T24 and UM-UC-3 cells (Figure 2C). It is noteworthy 
that overexpression and stabilization of this mutant 
does not restore its binding to Hsp90, likely because it 
lacks the C-terminal region of Tsc1 that binds to Hsp90 
(Supplementary Figure 2B) [17].
Our previous work has shown that the conditional 
knockout of TSC1 in mouse brain (Tsc1GFAPCKO) caused 
a significant increase in ATPase activity compared to the 
control samples [17]. Using those samples, we showed 
that Hsp90 is also hypoacetylated in Tsc1GFAPCKO tissue 
(Figure 2D, LE=long exposure, SE=short exposure). 
Therefore, we asked whether a similar phenomenon was 
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Figure 1: Tsc1 expression determines Hsp90 inhibitor accumulation and sensitivity in bladder cancer cells. (A) Tsc1 
status in T24, UM-UC-3 and RT4 bladder cancer cell lines was assessed by immunoblot. GAPDH was used as a loading control. (B) Lysates 
from Figure 1A were challenged with biotinylated-ganetespib. Binding of Hsp90 from T24, UM-UC-3 and RT4 cells to biotinylated-
ganetespib was examined by immunoblot. (C) TSC1 was targeted by siRNA in T24 and UM-UC-3 cells and Tsc1-FLAG was transiently 
expressed in RT4 cells. Representative confocal microscopy images of these cells treated for 4hr with BODIPY-ganetespib at the indicated 
concentrations and stained with DAPI. Scale bar = 50 µm. (D) Quantification of average fluorescence intensity of BODIPY-ganetespib in 
(C). A Student’s t-test was performed to assess statistical significance (**p < 0.01). (E) TSC1 was targeted by siRNA in T24 (left) and UM-
UC-3 (center) and Tsc1-FLAG was transiently expressed in RT4 (right) cells for 48 hr. Following this, cells were treated for an additional 
72 hr with the indicated concentrations of ganetespib. Cell proliferation was assessed by WST proliferation assay. A Student’s t-test was 
performed to assess statistical significance (*p < 0.05; **p < 0.01).
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Figure 2: Tsc1 facilitates acetylation of Hsp90. (A) Hsp90 was immunoprecipitated from TSC1 KO and TSC1 WT HAP1 cells and 
its serine, threonine, and tyrosine phosphorylation and lysine acetylation were examined by immunoblot. IgG was used as a control. (B) 
TSC1 KO HAP1 cells were transiently transfected with EV, Tsc1-TW-FLAG or Tsc1-L557Cfs-FLAG (mut.), the mutation found in the 
RT4 cell line. Acetylation of Hsp90 was then determined by immunoprecipitation and immunoblot. (C) Acetylation status of Hsp90 in T24, 
UM-UC-3 and RT4 determined by immunoprecipitation and immunoblot. (D) Hsp90 was immunoprecipitated from WT and astrocyte-
specific TSC1 KO mouse brain lysate and serine, threonine, and tyrosine phosphorylation and lysine acetylation of Hsp90 were assessed by 
immunoblot. LE=long exposure, SE=short exposure. (E) ATPase activity of Hsp90 isolated from TSC1 WT and TSC1 KO HAP1 cells. 10 
µM ganetespib was used as a control. A Student’s t-test was performed to assess statistical significance (n. s., not significant; *p < 0.05; ***p 
< 0.001). (F) Endogenous Hsp90 was isolated from MEF WT, Tsc1 KO or Tsc2 KO cells and acetylation was examined by immunoblot. 
Tsc1 and Tsc2 status was also examined. (G) HEK293 cells transiently expressing Hsp90α-WT-FLAG and empty plasmid (EV) was treated 
with rapamycin (20 nM) for 1 hr. Hsp90α-WT-FLAG was immunoprecepitated and its acetylation was evaluated by immunoblot. p70S6K 
and p-p70S6K (T389) were used to examine the inhibition of mTOR pathway.
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present in the TSC1 KO HAP1 cells. In agreement with 
our previously published data [17], we found that Hsp90 
isolated from TSC1 KO cells displayed increased ATPase 
activity compared to Hsp90 from WT HAP1 cells (Figure 
2E; Supplementary Figure 2C, 2D).
Finally, Tsc1-Tsc2 are involved in negatively 
regulating the mTOR signaling pathways. We therefore 
asked whether the effect of the Tsc1 mutation on Hsp90 
acetylation is independent of mTOR pathway. Endogenous 
Hsp90 isolated from TSC2 knock out mouse embryonic 
fibroblast cells (MEF) had a similar level acetylation as 
the Hsp90 isolated WT MEF cells (Figure 2F). As expected 
Hsp90 from TSC1 KO MEF cells was hypoacetylated 
(Figure 2F). Additionally treating HEK293 cells with 
rapamycin did not impact acetylation of Hsp90 (Figure 2G) 
suggesting the effect of Tsc1 mutation or loss on Hsp90 
acetylation is not mediated through the mTOR pathway.
Taken together, our results show that mutation 
and loss of Tsc1 stability and expression leads to 
hypoacetylation of Hsp90 and enhanced Hsp90 ATPase 
activity.
Tsc1 facilitates acetylation of Hsp90-K407/K419
Hypoacetylation of Hsp90 leads to its elevated 
ATPase activity; we therefore reasoned that lysine residues 
within the catalytic region of Hsp90 are candidates for 
PTMs. We identified two lysine sites (K407/K419) 
within this region that have been reported to be subject 
to acetylation (https://www.phosphosite.org//homeAction.
action; Figure 3A). We mutated these lysine residues to 
non-acetylatable alanine in Hsp90α individually and in 
combination and exogenously expressed them in CRISPR/
Cas9 HSP90AA1 KO HAP1 cells (Supplementary 
Figure 3A). Our data showed a reduction in acetylation 
of Hsp90α-FLAG-K407A and K419A and significant 
hypoacetylation of Hsp90α-FLAG-K407A/K419A 
suggesting that both of these residues are subject to 
acetylation (Figure 3B). It is noteworthy that K407 and 
K419 are not the only lysine sites that are acetylated on 
Hsp90α. Longer-exposure of immunoblots in Figure 3B 
confirms acetylation of Hsp90α and its mutants. Using 
anti-FLAG M2 agarose, we immunoprecipitated WT 
Hsp90α-FLAG as well as the lysine to alanine mutants 
from these cells and showed that Tsc1 interaction was 
completely abrogated in the K407A/K419A (AA) mutant 
(Figure 3C). We further demonstrated that Hsp90 was 
hypoacetylated in CRISPR/Cas9 TSC1 KO HAP1 cells 
to the same levels as the K407A/K419A (AA) mutant 
(Figure 3D), suggesting these lysine residues were 
the only sites affected as the result of TSC1 deletion. 
Finally, we demonstrated a significant reduction in 
binding of Hsp90α-K407A/K419A to biotinylated 
ganetespib, which demonstrates that acetylation of these 
two residues are important for Hsp90 inhibitor binding 
(Figure 3E, Supplementary Figure 3B). In aggregate, our 
results demonstrate that lack of Tsc1 expression leads to 
hypoacetylation of Hsp90 on K407/K419 and subsequent 
reduced binding of Hsp90 to its inhibitors.
HDAC inhibition rescues Hsp90 acetylation in 
TSC1-knock out cells
Histone deacetylases (HDAC) modify Hsp90 
[14, 31, 32], therefore we treated HEK293 cells with an 
HDAC inhibitor ACY-241 (acts as a pan-HDAC inhibitor 
at high dosage) for 16 hours, and showed hyperacetylation 
of Hsp90 (Figure 4A; Supplementary Figure 4A). We 
further utilized this pan-HDAC inhibitor to demonstrate 
that treatment of HEK293 cells expressing Hsp90α-
K407A/K419A does not increase the acetylation on 
this mutant (Figure 4B). This suggests that the effect of 
HDAC inhibition on Hsp90 is likely only through K407 
and K419. Finally, endogenous Hsp90 from TSC1 KO 
HAP1 cells is hypoacetylated but treating these cells with 
the HDAC inhibitor ACY-241 rescued Hsp90 acetylation 
(Figure 4C, Supplementary Figure 4B).
HDAC inhibition synergizes with Hsp90 
inhibition to induce apoptosis in bladder cancer
Mutation and inactivation of TSC1 in bladder cancer 
cells leads to decreased sensitivity to Hsp90 inhibitors. It 
appears that loss of Tsc1 may mediate this effect through 
Hsp90 hypoacetylation, which subsequently decreases 
Hsp90 inhibitor binding. We therefore treated the bladder 
cancer cells with a pan-HDAC inhibitor with the goal 
of restoring Hsp90 acetylation in Tsc1-mutant cells and 
subsequent sensitivity to Hsp90 inhibitors. Our initial data 
showed that Tsc1 mutated RT4 cells are more sensitive 
to the pan-HDAC inhibitor ACY-241 than WT Tsc1 
T24 or UM-UC-3 cells (Figure 5A), presumably due 
to hyperactivity of HDACs. We next treated RT4 cells 
with 50nM ACY-241 for 16 hours, followed by 500 nM 
ganetespib for further 48 hours. We further show that 
the co-treatment of ACY-241 and ganetespib yields a 
combination index score <1, (0.79412; Supplementary 
Figure 5A). Our results demonstrated synergistic effect of 
combination HDAC and Hsp90 inhibitor treatment on RT4 
cell proliferation (Figure 5B). Of note, the inhibitor doses 
used in the combination treatment were significantly lower 
than the IC50s of these drugs for RT4 cells. Additionally, 
combination treatment led to increased apoptosis as 
observed by immunoblot of cleaved caspase-3 (Figure 5C, 
Supplementary Figure 5B). We further confirmed that the 
sensitization of RT4 cells towards Hsp90 inhibitors as a 
result of HDAC co-inhibition was due to enhanced affinity 
of Hsp90 for ganetespib using biotinylated ganetespib 
binding assay (Figure 5D). Overall, our data provide 
evidence that inhibition of HDACs in bladder cancer cells 




The tumor suppressor TSC1 is a new co-chaperone 
of Hsp90 that modulates Hsp90 activity and enhances 
Hsp90 binding to its inhibitors [17, 20]. Mutations of 
TSC1 have been identified in 14.5% of bladder tumors 
and loss of heterozygosity of TSC1 has been reported 
approximately 54% of bladder cancers [21–26]. In this 
study we showed that mutation and loss of TSC1 in 
bladder cancer cells reduced the accumulation of Hsp90 
inhibitors in these cells and decreased cell sensitivity to 
Hsp90 inhibitors. We were able to rescue this effect by 
reintroducing WT Tsc1 suggesting that it is a Tsc1-specific 
effect.
Previous work by our group and others has 
shown that PTM of Hsp90 can modulate its binding 
and sensitivity to Hsp90 inhibitors [28–30, 33–35], we 
therefore asked whether Hsp90 was differentially modified 
in the absence of Tsc1. Mechanistically, we demonstrated 
that presence of Tsc1 resulted in acetylation of two lysine 
residues (K407/K419) near the catalytic site in the middle-
domain of Hsp90. Mutation or absence of TSC1 led to 
hypoacetylation of Hsp90 and this was demonstrated 
in Hsp90 isolated from four cell types lacking TSC1: 1) 
Figure 3: Tsc1 facilitates acetylation of Hsp90-K407/K419. (A) Structure of an Hsp90 dimer (PDB:2CG9). K407 and K419 are 
highlighted on one protomer in red. (B) FLAG-tagged Hsp90α-WT or non-acetylatable mutants K407A, K419A, or K407/K419A were 
transfected into HSP90α KO HAP1 cells. Acetylation status was determined by immunoprecipitation and immunoblot. LE=long exposure, 
SE=short exposure. (C) Tsc1 interaction with Hsp90 and acetylation mutants was assessed by FLAG immunoprecipitation of Hsp90 from 
lysates in (B). (D) Hsp90 acetylation was determined by immunoprecipitation and immunoblot of Hsp90α-WT-FLAG and Hsp90α-K407/
K419A-FLAG from TSC1 WT and TSC1 KO HAP1 cells. (E) Lysates from Figure 3B were challenged with biotinylated-ganetespib. 
Binding of Hsp90α-FLAG from these lysates to biotinylated-ganetespib was examined by immunoblot.
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Figure 4: HDAC inhibition rescues Hsp90 acetylation in TSC1-knock out cells. (A) Endogenous Hsp90 was immunoprecipitated 
from HEK293 cells treated with or without 1 µM pan-HDAC inhibitor ACY-241 for 16 hr and its acetylation status was determined 
by immunoblot. (B) Hsp90α-WT-FLAG and non-acetylatable mutant K407/K419A were transiently expressed in HEK293 cells in the 
presence or absence of 1 µM ACY-241 for 16 hr. Acetylation status was evaluated by immunoprecipitation followed by immunoblot. 
LE=long exposure, SE=short exposure. (C) TSC1 WT HAP1 cells and TSC1 KO HAP1 cells were treated with or without 1µM ACY-241 
for 16 hr. Endogenous Hsp90 was isolated and its acetylation status was examined by immunoblot.
Figure 5: HDAC inhibition synergizes with Hsp90 inhibition to induce apoptosis in bladder cancer. (A) Sensitivity of T24, UM-
UC-3 and RT4 cells to increasing concentrations of ACY-241 was determined by WST proliferation assay. A Student’s t-test was performed to 
assess statistical significance (***p < 0.001). (B) RT4 cells were treated with or without 0.5µM ACY-241 for 16 hr followed by 0.5µM ganetespib 
for an additional 48 hr. Cell viability was then determined by WST proliferation assay. A Student’s t-test was performed to assess statistical 
significance (***p < 0.001). (C) Immunoblot of apoptotic marker cleaved caspase-3 in RT4 cells from (B). (D) Hsp90 binding to biotinylated-
ganetespib was examined in RT4 cells treated with or without 1 µM ACY-241 for 16 hr. (E) Impact of the co-chaperone Tsc1 on Hsp90 binding 
to its inhibitors. Tsc1 facilitates acetylation of Hsp90-K407/K419. In the absence of Tsc1, Hsp90 is hypoacetylated at these residues and binds 
less avidly to its inhibitors. HDAC inhibitor treatment restores Hsp90 acetylation and bladder cancer cell sensitivity to Hsp90 inhibitors.
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bladder cancer cells with TSC1 mutation, 2) TSC1 KO 
HAP1 cells, 3) conditional knockout of TSC1 in mouse 
brain and 4) TSC1 KO MEFs. Interestingly the effect of 
the Tsc1 mutation on Hsp90 acetylation appears to be Tsc1 
specific and independent of the mTOR pathway, Hsp90 
acetylation was unaffected both in TSC2 KO MEFs and in 
HEK293 cells treated with the mTOR inhibitor rapamycin.
Hypoacetylation of Hsp90 enhances its ATPase 
activity and reduces binding to its inhibitors. Determination 
of precisely how Tsc1 loss leads to hypoacetylation of 
Hsp90 and which HAT or HDAC enzymes are involved 
will require further investigation. However, increasing 
Hsp90 acetylation through HDAC inhibition with ACY-
241 resulted in enhanced Hsp90 inhibitor binding as well 
as sensitization to Hsp90 inhibitors in the TSC1 mutated 
RT4 bladder cancer cell line.
HDAC6 mediated deacetylation of Hsp90 and 
regulation of its chaperone function has been reported 
previously [31, 32]. In fact our data are also in agreement 
with those published previously, confirming acetylation 
of Hsp90 leads to its inhibition. Therefore based on 
our findings presented here we would like to propose 
the following model, where in the presence of Tsc1 co-
chaperone Hsp90 is acetylated and has a high affinity 
towards its N-domain inhibitors such as ganetespib 
(Figure 5E). Mutation and inactivation of TSC1, such as 
those frequently observed in bladder cancer cells leads 
to hypoacetylation of Hsp90, enhanced ATPase activity, 
and reduced binding to inhibitors (Figure 5E). This also 
reduces the sensitivity of bladder cancer cells to the 
Hsp90 inhibitors. This suggests that TSC1 status may 
predict sensitivity to Hsp90 inhibitors in bladder cancer. 
Additionally, in those patients with TSC1 mutated bladder 
cancer, inhibition of HDACs can potentially restore 
Hsp90 acetylation and sensitivity to Hsp90 inhibitors.
MATERIALS AND METHODS
Mice
All mouse experiments were performed under the 
ethical guidelines of the Washington University School 
of Medicine, and animal protocols were reviewed and 
approved by the Washington University School of 
Medicine Institutional Animal Care and Use Committee 
(IACUC #A-3381-01; Protocol #20160091). All mice 
used in this study were obtained from an existing breeding 
colony of Tsc1GFAPCKO mice (Uhlmann et al, 2002; Zeng 
et al, 2008) in the animal facility of the Washington 
University School of Medicine.
Mammalian cell culture
Human embryonic kidney (HEK293), T24, UM-
UC-3, and RT4 cells were acquired from the American 
Type Culture Collection (ATCC). TSC1 KO, HSP90α 
KO, and wild-type HAP1 cells were acquired from 
Horizon Discovery. HEK293, UM-UC-3, WT MEF, 
TSC1 KO and TSC2 KO MEFs cells were grown in 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma–
Aldrich), T24 and RT4 cells were grown in McCoy’s 5A 
Medium (Sigma–Aldrich) and HAP1 cells were grown 
in Isocove’s Modified Dulbecco’s Medium (IMDM, 
Gibco) supplemented with 10% fetal bovine serum (FBS, 
Sigma–Aldrich). Cells were grown in a CellQ incubator 
(Panasonic Healthcare) at 37° C in an atmosphere 
containing 5% CO2.
Plasmids




HSP90α-FLAG-K407A, HSP90α-FLAG-K419A, and 
HSP90α-FLAG-K407/K419A were generated by site-







Mutations were confirmed by DNA sequencing.
Transient transfection and siRNA knock-down
HEK293 cells were transiently transfected with 
each construct using TransIT®-2020 (Mirus) transfection 
reagent according to company protocol and incubated 
at 37° C for 16 hours prior to protein extraction. Short 
interfering RNA (siRNA) scramble control and TSC1 
(Tsc1) targeting duplexes were purchased from GE 
Dharmacon and suspended in provided buffer. For Tsc1 
knock-down, either 30 nM of control siRNA or 10 nM 
of each Tsc1 siRNA duplex (A, B and C) were mixed 
prior to transfection. Cells were incubated at 37° C then 
harvested for protein extraction (see below) or placed into 
downstream applications as described below.
Protein extraction, immunoprecipitation, and 
immunoblotting
Protein extraction from mammalian cells was 
carried out using methods previously described [30]. For 
immunoprecipitation, protein lysates were incubated with 
anti-FLAG M2 Affinity Gel agarose (Sigma) for 2 hr at 
4° C. Alternatively, for endogenous immunoprecipitation, 
protein lysate was incubated with Hsp90 antibody for 
2 hr followed by incubation with protein G agarose 
(Qiagen) for 2 hr at 4° C. Immunopellets were washed 
4 times with fresh lysis buffer (20mM Tris (pH7.4), 100 
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mM NaCl, 1 mM MgCl2, 0.1% NP40, protease inhibitor 
cocktail (Roche), and PhosSTOP (Roche)) and eluted 
with 5× Laemmli buffer. Precipitated proteins were 
separated by SDS-PAGE and transferred to nitrocellulose 
membranes. Co-immunoprecipitated proteins were 
detected by immunoblotting with indicated dilutions 
of antibodies. Primary antibodies recognizing FLAG 
1:8000 (ThermoFisher Scientific; PA1-984B), Hsp90-
835-16F1 1:8000 (ENZO Life Sciences; ADI-SPA-835), 
GAPDH 1:8,000 (ENZO Life Sciences; ADI-CSA-335), 
Tsc1 1:1000 (Cell Signaling Technology (CST); 4906), 
Tsc2 1:1000 (CST; 3990), K-Ac 1:1000 (CST; 9441), 
phos-Ser 1:1000 (Sigma; P5747), phos-Thr 1:1000 
(Sigma; P6623), phos-Tyr 1:1000 (Millipore; 05-321), 
Phospho-p70 S6 Kinase (Thr389) (108D2) 1:2000 (CST; 
9234), p70S6K 1:6000 (SantaCruz Biotechnology; 
sc-8418), and cleaved-caspase-3 1:1000 (CST; 9661) 
were used for immunoblotting. Endogenous Hsp90 was 
immunoprecipitated with Hsp90-835-16F1 (ENZO 
Life Sciences; ADI-SPA-835) at 1:1000 dilution. HRP-
conjugated secondary antibodies raised against mouse, 
rabbit, and rat (Cell Signaling Technology) were used at 
1:4000 dilution.
Fluorescence microscopy
T24 and UM-UC-3 cells were transiently 
transfected with siRNA targeting Tsc1 and RT4 cells were 
transfected with Tsc1-FLAG for 48 hr as described above, 
then trypsinized and plated overnight on glass coverslips 
(#1). After 16 hr, BODIPY-ganetespib was added to 
cells at the indicated concentrations for an additional 
4 hr. Cells were fixed in 4% paraformaldehyde for 20 
minutes at room temperature and washed 3× with fresh 
PBS. Coverslips were then mounted onto glass slides 
using ProLong® Gold antifade mounting media with 
DAPI (4′,6-diamidino-2-phenylindole) (ThermoFisher 
Scientific). Images were obtained using a Zeiss LSM780 
confocal microscope.
Cell proliferation colorimetric (WST) assay
T24, UM-UC-3 were seeded at 5,000 cell/well after 
siRNA TSC1 knock-down and RT4 cells were seeded at 
10,000 cells/well alone or after Tsc1-FLAG expression 
as described above in 96-well plates. Cells were treated 
with indicated concentrations of ACY-241 (Celgene 
Corporation) and/or ganetespib as indicated. After 72 hr, 
cell proliferation colorimetric (WST) assay was performed 
according to the manufacturer’s protocol (BioVision, Cat# 
K302-500). In brief, 10 μl WST was added to each well 
and the plate was returned to the 37° C incubator. After 60 
minutes, absorbance at 450nm was measured on a Tecan 
Infinite M200 Pro and proliferation rate was calculated. 
For transfected/siRNA knockdown cells, transfections 
were incubated for 48 hours prior to trypsinization and 
plating in the 96-well plate.
Hsp90 ATPase assay
ATPase activity of Hsp90 was measured as 
previously described (Kamal et al. 2003) with the following 
additional details. Following protein extraction and 
immunoprecipitation as described above in the Materials 
and Methods, protein-bound Protein-G agarose (Qiagen) 
was washed five times in 0.5M NaCl and 1% NP-40 
buffer. Proteins were eluted from the beads twice with 
50µl 0.1M glycine pH 3.0 and immediately neutralized 
using an equal volume of Tris pH 8.0. Protein was then 
concentrated with Amicon® Ultra-2 mL, 10K centrifugal 
filters (Millipore). Using the Micro BCATM Protein 
Assay Kit (Thermo Scientific), protein was quantified to 
standardize the amount of protein used in the assay. Assay 
was performed as described in the PiPer
TM Phosphate Assay 
Kit instructions for use (Life Technologies). Standard 
curve with linear fit line was created from 0-100µM final 
concentration reactions. Hsp90 was incubated at 37°C 
for 1 hr with 100mM ATP as substrate, with or without 
10µM ganetespib (Synta Pharmaceuticals). ATP turnover 
was calculated as mmol Pi per mol Hsp90 per minute, and 
relative ATPase activity was calculated from those values, 
with the value of Hsp90α alone representing 100% activity.
Quantification and statistical analysis
The relationship of drug co-treatment was 
measured through an isobologram. The ED50 of each 
drug was plotted in Cartesian co-ordinates on an X, 
Y graph and a best fit line drawn. The co-ordinates of 
the ED50 for the co-treatment of the drugs was further 
plotted. The offset of the combined drugs from the best 
fit line is given as the combination index with equation: 
[ ] [ ]
 
50[ ] 50[ ]
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CI
ED A ED B
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 The data presented are the 
representative or examples of three biological replicates 
unless it is specified. Data were analyzed with unpaired 
Student’s t-test. Asterisks in figures indicate significant 
differences (*p < 0.05, **p < 0.01, ***p < 0.001, and ***p < 
0.0001). Error bars represent the standard deviation (S. D.) 
for three independent experiments, unless it is indicated.
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